Jones Financial Companies Lllp Has $1.14 Million Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• Jones Financial Companies Lllp reduced its stake in Boston Scientific Corporation by 26.6%, holding 11,288 shares valued at approximately $1.14 million as of the latest SEC filing.
• Boston Scientific reported a quarterly revenue of $5.06 billion, exceeding analyst expectations, with an EPS of $0.75 compared to the consensus estimate of $0.72.
• Several institutional investors have increased their positions in Boston Scientific, with 89.07% of the stock owned by institutional investors, highlighting strong market interest.

Jones Financial Companies Lllp trimmed its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 26.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,288 shares of the medical equipment provider's stock after selling 4,088 shares during the quarter. Jones Financial Companies Lllp's holdings in Boston Scientific were worth $1,139,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in shares of Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock valued at $13,577,311,000 after purchasing an additional 1,697,945 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Boston Scientific by 5.3% during the first quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock valued at $1,677,124,000 after purchasing an additional 834,274 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock valued at $1,426,779,000 after purchasing an additional 1,383,524 shares in the last quarter. Amundi boosted its stake in shares of Boston Scientific by 2.6% during the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider's stock valued at $1,212,408,000 after purchasing an additional 311,034 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Boston Scientific by 18.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 10,839,362 shares of the medical equipment provider's stock valued at $968,172,000 after purchasing an additional 1,709,461 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Trading Down 1.6%

NYSE BSX opened at $102.71 on Friday. The company has a market cap of $152.19 billion, a price-to-earnings ratio of 61.14, a P/E/G ratio of 2.51 and a beta of 0.65. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50. The business has a 50 day moving average price of $104.86 and a 200-day moving average price of $102.26. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific's quarterly revenue was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Edward J. Ludwig sold 4,000 shares of the company's stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the transaction, the director owned 18,479 shares of the company's stock, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director directly owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 174,214 shares of company stock worth $18,397,457 in the last ninety days. Company insiders own 0.50% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on BSX shares. Leerink Partners started coverage on Boston Scientific in a research note on Monday, June 16th. They issued an "outperform" rating and a $118.00 price objective on the stock. Citigroup reaffirmed a "buy" rating and issued a $125.00 price objective (up from $119.00) on shares of Boston Scientific in a research note on Thursday, May 22nd. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Boston Scientific in a research note on Thursday, July 24th. Raymond James Financial lifted their price objective on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 24th. Finally, Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $118.04.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.